Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of biopharmaceuticals, particularly monoclonal antibodies and biosimilars. The company operates primarily in China, with a growing presence in international markets, leveraging its advanced manufacturing capabilities and a strong pipeline of innovative therapies to drive future growth.
Kelun-Biotech generates revenue through the sale of its proprietary biopharmaceutical products, which are often priced at a premium due to their innovative nature. The company benefits from a strong R&D pipeline and has established partnerships with global pharmaceutical firms, enhancing its market reach and distribution capabilities.
Regulatory approvals for new drug candidates, particularly in the U.S. and EU markets
Partnership announcements with global pharmaceutical companies
Clinical trial results for key pipeline products
Market expansion efforts into Europe and North America
Regulatory changes impacting drug approval processes
Technological disruption in biopharmaceutical manufacturing
Emerging biosimilar competitors in the Chinese market
Potential loss of patent protection for key products
Negative cash flow impacting liquidity
High R&D costs leading to potential future funding challenges
moderate - The biotechnology sector can be sensitive to economic cycles, as healthcare spending may decline during downturns, impacting revenue.
Interest rates affect Kelun-Biotech's cost of capital for R&D funding and may influence investor sentiment regarding growth stocks, potentially compressing valuation multiples.
minimal - The company has a low debt-to-equity ratio (0.02), indicating limited reliance on external financing.
growth - Investors are likely attracted to the potential for high revenue growth from innovative biopharmaceutical products.
high - The stock has shown significant price fluctuations, evidenced by a 32.6% return over the past year but a recent 12.2% decline in the last three months.
